Skip to Content

Press Releases

Press Releases

Mar 12 2018
Intec Pharma Partners with LTS for Manufacture of Accordion Pill Carbidopa/Levodopa for Treatment of Parkinson's Disease
Global leader in formulation and film technology manufacture to establish commercial scale production capabilities for Intec's lead product candidate in FDA compliant facility JERUSALEM, March 12, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ, TASE: NTEC) ("Intec" or the "Company") today announces
Mar 09 2018
Intec Pharma Reports Fourth Quarter and Year End 2017 Financial Results and Business Update
More than 300 patients enrolled in pivotal Phase 3 ACCORDANCE Trial Gastroscopy safety sub-study successfully completed JERUSALEM, March 9, 2018 /PRNewswire/ --   Intec Pharma LTD (NASDAQ: NTEC) (TASE: NTEC) today announces financial results for the three and twelve months ended December 31,
Mar 05 2018
Intec Pharma, Ltd. to Present at Four Investor Conferences in March
JERUSALEM, March 5, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC), a clinical-stage biopharmaceutical company focused on developing pharmaceutical therapies based on its proprietary Accordion Pill™ platform technology, today announced that the Company's officers will provide a corporate
Jan 31 2018
Intec Pharma Names R. Michael Gendreau, M.D., Ph.D. as Chief Medical Officer
Industry Veteran brings over 30 years of experience in drug development JERUSALEM, Jan. 31, 2018 /PRNewswire/ --   Intec Pharma Ltd. (NASDAQ:  NTEC) (TASE:  NTEC ), a clinical stage biopharmaceutical company focused on developing pharmaceutical therapies based on its proprietary Accordion
Jan 08 2018
Intec Pharma Announces Development Collaboration With Global Pharmaceutical Company
JERUSALEM, January 8, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, today announced it has entered into a Feasibility and Option agreement with
Jan 03 2018
Intec Pharma Granted Patent in Canada for Accordion Pill™ Carbidopa / Levodopa
JERUSALEM, January 3, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) (TASE: NTEC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill TM  platform technology, today announced that the Canadian Intellectual Property Office has issued
Nov 15 2017
Intec Pharma Reports Third Quarter 2017 Operating and Financial Results
· Closed equity offering of $57.5 million; Cash of $64.7 million at September 30, 2017 · Expanding planned enrollment to 420 patients in its Phase 3 ACCORDANCE Trial; enrollment to be completed in the third quarter of 2018 · Formed new U.S. Medical Affairs and U.S.
Nov 08 2017
Intec Pharma, Ltd. to Present at the Jefferies 2017 London Healthcare Conference
JERUSALEM, November 8, 2017 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ, TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, today announced that Jeffrey Meckler, Chief Executive Officer, will provide a
Nov 01 2017
Intec Pharma Ltd. Announces Changes to its Board of Directors
JERUSALEM, November 1, 2017 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq, TASE: NTEC), a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, today announced that Mr. Zvi Joseph, founder and Mr. Giora Carni, former CEO of
Oct 26 2017
Mr. Linscott brings three decades of broad experience to new role
JERUSALEM, October 26, 2017 /PRNewswire/ -- Intec Pharma Ltd. (Nasdaq: NTEC) (TASE: NTEC), a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill™ platform technology, today announced it has named Mr. Walt Linscott to the position of Chief
Displaying 41 - 50 of 98